5 Weight Loss Injection Myths You Need to Stop Believing

Two in three Australian adults were living with overweight or obesity in 2022 — around 13 million people. That’s a staggering number, and it helps explain why weight loss medications have moved from specialist clinics into everyday conversation. Suddenly everyone has an opinion about Ozempic, Wegovy, Mounjaro, “fat jabs”, miracle fixes, side effects, and whether any of it is actually legit.

If you’ve been Googling weight loss injections Australia, trying to make sense of GLP-1 myths, or bouncing between social media hot takes and old-school diet myths, you are absolutely not alone. The problem is that a lot of the loudest advice is either oversimplified, outdated, or flat-out wrong. And when a topic affects your health, your money, your confidence and your long-term wellbeing, bad information is more than annoying — it can push people into unsafe choices.

So let’s clear the air. In this guide, we’ll unpack five of the most common myths about GLP-1 weight loss medications, explain what these injections actually do, and cover the practical realities that often get squeezed out of a short GP appointment: who may be eligible, how these medicines differ in Australia, what side effects matter, why stopping treatment can be tricky, and why buying from random online sellers is a terrible idea. If you want an even more basic explainer first, our guide to GLP-1 Weight Loss Medications Explained Simply is a good place to start.

First, what are GLP-1 weight loss medications?

In simple terms, GLP-1 medications mimic or affect gut hormones involved in appetite, fullness, blood sugar regulation and gastric emptying. That’s why people on these medicines often say they feel full sooner, snack less, or think about food less often. In Australia, medicines in this space include semaglutide, liraglutide and tirzepatide, and they are used for type 2 diabetes, obesity, or both depending on the specific product and indication.

That last bit matters. “GLP-1” is often used like it’s one single thing, but it’s really a class label people throw around for several different prescription medicines. If you want the Australian-specific version, healthdirect’s weight loss medicine overview and the Australian Prescriber article on injectable drugs for weight management are both solid reads. For a more practical NextClinic take, you can also read Am I Eligible for Weight Loss Medication in Australia?.

Myth 1: Weight loss injections are just a shortcut for people who don’t want to “eat better and exercise”

This is probably the most tired of all the diet myths — and one of the least useful.

The reality is that GLP-1 weight loss medications are not magic, but they are also not fake. They work through real biological pathways that influence hunger, satiety and food intake. Australian guidance is very clear that these medicines are meant to be used as an adjunct to a reduced-energy diet and increased physical activity, not as a replacement for every other part of health. That doesn’t make them a shortcut. It makes them a medical tool.

It also ignores something important: obesity is not simply a willpower problem. The RACGP notes that obesity is a chronic disease shaped by biological, environmental and socioeconomic factors, and that lifestyle efforts alone often run into the body’s built-in drive to defend weight. That’s one reason pharmacotherapy can be helpful for some people. In other words, if someone needs medical support for weight management, that is not a character flaw.

And yes, these medicines can produce meaningful results. In a major trial, weekly semaglutide 2.4 mg plus lifestyle intervention produced an average weight reduction of about 14.9% at 68 weeks; in SURMOUNT-1, weekly tirzepatide produced average reductions of about 15.0% to 20.9% at 72 weeks depending on dose. Those are significant effects — but they happened in structured trials with dose titration, monitoring and lifestyle support, not in a fantasy world where people injected once and never changed another habit.

So no, weight loss injections are not an “easy way out”. But they’re also not a free pass to ignore food quality, movement, sleep, alcohol intake, stress or follow-up care. The smartest mindset is this: medicine can lower the noise and create a window of opportunity, but you still need a plan for what you do with that window.

Myth 2: Ozempic, Wegovy and Mounjaro are basically the same thing

This one causes a lot of confusion in Australia, especially when people use “Ozempic” as a catch-all term for every injectable weight loss medication.

They are not all the same. Ozempic contains semaglutide and, in Australia, is indicated for adults with insufficiently controlled type 2 diabetes, along with certain kidney and cardiovascular risk indications in that context. Wegovy also contains semaglutide, but it is the product specifically indicated for chronic weight management. Mounjaro contains tirzepatide, a dual GIP/GLP-1 medicine, and in Australia it has indications for type 2 diabetes and chronic weight management.

There are other differences too. Wegovy is weekly. Mounjaro is weekly. Saxenda, which contains liraglutide, is a daily injection. Their dosing schedules, approved uses, side-effect profiles, costs and practical prescribing decisions are not identical. That means your friend’s experience on one medicine does not automatically tell you what your experience on another will be.

This is exactly why brand-name chatter online can be misleading. “I want Ozempic” is not the same as “I want evidence-based treatment for obesity that is legal, appropriate and actually suited to my history.” If you want a more detailed breakdown, our articles on Wegovy Prescription Australia and Is Mounjaro Better Than Wegovy? go deeper into the differences.

Myth 3: If you want weight loss injections badly enough, you can just get them online

This myth is dangerous because it mixes one true thing with several false ones.

The true part: telehealth can absolutely play a legitimate role in prescribing in Australia. The false part: that any website can safely hand out weight loss medications after a quick form and a payment screen. The Medical Board of Australia’s telehealth guidance says prescribing or providing healthcare without a real-time direct consultation — in person, by video or by telephone — is not good practice. Good telehealth is still real medicine. It just happens remotely.

There’s also the question of eligibility. Australian guidance generally frames anti-obesity pharmacotherapy for adults with a BMI of 30 or more, or 27 or more with at least one weight-related complication such as type 2 diabetes, hypertension, dyslipidaemia, sleep apnoea or similar conditions. But that’s not the whole story. A prescriber also has to think about contraindications, current medicines, side effects, pregnancy plans, previous response to treatment and whether a different approach makes more sense.

And then there’s the counterfeit problem. In March 2026, the TGA issued an updated safety advisory after testing confirmed counterfeit imported weight loss products falsely claiming to contain GLP-1 ingredients. That means the “cheap online alternative” you found on social media may not be a bargain — it may not even be the medicine it claims to be. The TGA advises Australians to buy prescription medicines only from a local registered pharmacy and not from unregistered sellers online or through social platforms.

At NextClinic, we think convenience matters — but so do standards. That’s why our approach to telehealth is built around proper clinical assessment, not click-and-ship medicine. If you’re curious about how that works in Australia, read Can You Get a Script Without a Video Call?.

Myth 4: Side effects are either no big deal… or they mean the medicine is “working”

Both versions are wrong.

The most common side effects with these medicines are usually gastrointestinal: nausea, vomiting, diarrhoea, constipation, abdominal discomfort and related symptoms. That’s one reason dose escalation tends to happen gradually rather than jumping straight to a higher dose. Mild side effects do not automatically mean something is wrong, but they also should not be brushed off as some kind of badge of honour. Feeling miserable is not the goal of treatment.

More importantly, these medicines are not “safe for everyone”. Australian GP guidance notes that anti-obesity medicines are contraindicated during pregnancy and lactation, and pregnancy planning should be part of the prescribing conversation. For tirzepatide specifically, the TGA updated advice to say that reduced effectiveness of oral contraceptives during initiation or dose escalation could not be ruled out, and patients using oral contraception should switch to a non-oral method or add a barrier method for 4 weeks after starting and for 4 weeks after each dose increase. That is a huge practical detail — and a very relevant one for sexual and reproductive health.

There are also procedural issues people don’t always hear about on TikTok. The TGA has required warnings for GLP-1 and dual GIP/GLP-1 medicines about delayed gastric emptying and the risk of inhaling stomach contents during general anaesthesia or deep sedation. So if you’re taking one of these medicines and you’re having surgery, a procedure or deep sedation, tell your treating team. That’s not a niche detail. That’s clinically important.

So the healthy middle ground is this: don’t panic over every bit of nausea, but don’t romanticise side effects either. A good prescribing plan includes knowing what’s common, what’s manageable, what’s a red flag, and when to get help.

Myth 5: Once you hit your goal weight, you can stop the injections and the weight will stay off forever

This is the myth people most want to be true.

The problem is that obesity is generally treated as a chronic condition, not a one-off project with a neat finish line. Australian GP guidance says most individuals require long-term therapy, and that stopping obesity-modifying medication is associated with weight regain and recurrence of weight-related comorbidities for many people. That doesn’t mean everyone regains weight at the same pace or to the same extent. It does mean that “I’ll just use it for a few months and be done forever” is usually not a realistic expectation.

The trial literature points in the same direction. Follow-up data after semaglutide withdrawal showed that weight regain can occur after treatment stops, and reviews of the STEP program similarly conclude that continued treatment helps maintain results better than withdrawal. This isn’t because the medicine “failed”. It’s because the underlying biology didn’t vanish just because the number on the scale improved.

This matters for two reasons. First, people deserve honesty before they start. Second, it changes what success looks like. Success is not just “How fast did I lose weight?” It is also “Can I afford this? Can I tolerate it? What’s the long-term plan? What habits am I building while treatment is helping me?” Those are much better questions than “How quickly can I get the skinny jab everyone is talking about?”

What your GP might not have time to tell you in a 10-minute appointment

Not because your GP is hiding anything — just because this topic is bigger than a rushed consult.

Here are a few realities worth asking about:

• The brand name is not the treatment plan. Ask what medicine is being considered, what it’s actually approved for in Australia, and why that specific option fits your history better than another. Ozempic, Wegovy and Mounjaro are not interchangeable in every situation.
• Lifestyle support still matters, even when medicine helps. Australian guidance consistently frames these medicines as adjuncts to reduced-energy eating patterns and physical activity. The Australian Dietary Guidelines and the physical activity recommendations for adults are boring compared with a viral before-and-after photo, but they are still the foundation.
• Affordability is a real health issue. The PBS is still working through questions of equitable access to GLP-1 obesity treatments, and broad subsidy for obesity remains limited. In plain English: many Australians seeking these medicines for weight management still pay privately, and that can shape what is realistic long term.
• Pregnancy, contraception and sexual health are not side notes. If you are pregnant, planning pregnancy, breastfeeding, or relying on the pill while using tirzepatide, that needs to be discussed upfront — not as an afterthought.
• Your other medicines may need adjustment. As weight, appetite, blood pressure or blood glucose change, other medications may need reviewing too. A proper plan includes follow-up, not just a script.
• Where you buy the medicine matters. Prescription-only medicines should come through a legitimate prescriber and a registered pharmacy, not a social media seller, a dodgy “wellness” site, or a mystery vial shipped from overseas.

If you want to keep reading after this, our posts on Am I Eligible for Weight Loss Medication in Australia?, Wegovy Prescription Australia, and GLP-1 Weight Loss Medications Explained Simply walk through the practical Australian side in more detail.

The bottom line

Weight loss injections are not a scam, not a miracle, and not a personality test. They are prescription medicines with real benefits, real limits and real risks. The biggest myths to let go of are these: that they’re just laziness in a pen, that all brands are the same, that anyone can safely buy them online, that side effects don’t matter, and that stopping treatment always leaves results untouched. None of that matches the evidence or the Australian prescribing reality.

A better approach is to swap hype for questions: What medicine is this, exactly? Is it appropriate for me? What support should go with it? What are the side effects I need to watch? What’s the long-term plan? That’s the conversation that turns confusion into informed care. And that’s far more useful than another recycled diet myth dressed up as “hard truth.”

This week, pick one practical strategy and act on it: book a proper medical review, read the healthdirect weight loss medicine guide, check whether your expectations are realistic, or build one sustainable habit that would still help you even without medication — like a daily walk, a more filling breakfast, or a plan for regular meals. Then come back and tell us in the comments which strategy you chose and how it went. We’d love to hear what’s actually working for you.

References

• Overweight and obesity, About - Australian Institute of Health and Welfare
• Weight loss medicine | healthdirect
• GLP-1 Weight Loss Medications Explained Simply | NextClinic
• Injectable drugs for weight management - Australian Prescriber
• Once-Weekly Semaglutide in Adults with Overweight or Obesity - PubMed
• Ozempic | healthdirect
• Wegovy Prescription Australia
• Guidelines:
• Counterfeit weight loss products claiming to contain GLP-1 | Therapeutic Goods Administration (TGA)
• Can You Get a Script Without a Video Call?
• Medicines containing GLP-1 and dual GIP/GLP-1 receptor agonists | Therapeutic Goods Administration (TGA)
• Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations - PMC
• Pharmaceutical Benefits Scheme (PBS) | Pharmaceutical Benefits Advisory Committee (PBAC) advice on equitable access to GLP-1 obesity treatments
• Am I Eligible for Weight Loss Medication in Australia? | NextClinic

FAQs